Health ❯ Healthcare ❯ Clinical Trials

Phase III Trials

MATTERHORN Trial Efficacy Studies KOMET Trial ASPEN Trial Daraxonrasib TULIP-SC Trial Giredestrant Trials Patient Outcomes DESTINY-Breast05 Trial Drug Safety

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

The findings set up an FDA decision due by August 5.

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

Moderna Begins Phase III Trial of mRNA Bird Flu Vaccine in UK and US

Roche Files MS Drug Fenebrutinib With Regulators Despite Trial Deaths

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

FDA Clears Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

Lancet Phase III Trial Finds Proton Therapy Improves 5-Year Survival in Oropharyngeal Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control